Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132733 | 0.87 | ESR2 (0.53) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL19005682 | 0.87 | ESR2 (0.53) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL24535216 | 0.85 | ESR2 (0.48) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL22030526 | 0.81 | PARP1 (0.40) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL21807285 | 0.80 | MAPK1 (0.52) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL31233749 | 0.80 | NR1H2 (0.49) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL1171647 | 0.79 | ESR2 (0.48) | NR1H2MAPK1ESR2MAPTUSP2 | |
| SCHEMBL26260560 | 0.78 | NR1H2 (0.39) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL23794828 | 0.78 | NR1H2 (0.39) | NR1H2MAPK1ESR2DDB1CRBN | |
| SCHEMBL9944477 | 0.78 | NAMPT (0.36) | NR1H2NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106905325-B | Preparation method of augustine intermediate | 济南同路医药科技发展有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| EP-4673448-A1 | SUBSTITUTED NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024254990-A1 | COMPOUND HAVING HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-12-19 | — | — | WO | disclosed |
| CN-119143747-A | Heteroaromatic ring structure compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240408107-A1 | LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| CN-118843616-A | Benzamide compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118772110-A | Heteroarone compounds and their use as LSD1 inhibitors | 上海复星医药（集团）股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-2820017-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | Genentech, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8853212-B2 | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2013127269-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH,INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013127267-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2571876-A1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2538783-A1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120277240-A1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. | 2012-11-01 | — | — | US | disclosed |
| WO-2011146358-A1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011103256-A1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277240-A1 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | NR1H2 2030/4885MAPK1 4188/4885ESR2 2751/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | NR1H2 1163/4885MAPK1 1355/4885ESR2 2383/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | NR1H2 658/4885MAPK1 2177/4885ESR2 4393/4885 |
| US-20240408107-A1 | LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PKM, PDK3 | NR1H2 2814/4885MAPK1 706/4885ESR2 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.